Who is on it, and how far along Every drug ChEMBL records acting on BCL2, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved1 Venetoclax Venetoclax SponsorAbbVie ModalitySmall molecule ActionInhibitor Open trials538 Phase 32 Navitoclax Navitoclax SponsorAbbVie ModalitySmall molecule ActionInhibitor Open trials10 Obatoclax Obatoclax SponsorGemin X ModalitySmall molecule ActionInhibitor Open trials0 Phase 21 APG-2575 APG-2575 SponsorAscentage Pharma Group Inc. ModalityOther ActionInhibitor Open trials20
The landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Apoptosis regulator Bcl-2 inhibitor.
Open trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL Venetoclax Phase 2 Not yet recruiting Ruijin Hospital Nov 17, 2026 Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia Venetoclax Phase 1 / Phase 2 Not yet recruiting Second Affiliated Hospital of Nanchang University Nov 9, 2026 A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients Venetoclax Phase 3 Recruiting Beijing InnoCare Pharma Tech Co., Ltd. Nov 9, 2026 Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL Venetoclax Not applicable Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China Nov 6, 2026 This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax. Venetoclax Not applicable Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Oct 14, 2026 Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML Venetoclax Phase 2 Not yet recruiting Rutgers, The State University of New Jersey Oct 9, 2026 Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Venetoclax Phase 2 Not yet recruiting National Cancer Institute (NCI) Oct 7, 2026 Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients Venetoclax — Not yet recruiting Assiut University Oct 1, 2026 Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL APG-2575 Phase 2 Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China Sep 21, 2026 Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure APG-2575 Phase 2 Enrolling by invitation Guangdong Second Provincial General Hospital Sep 10, 2026 Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) APG-2575 Phase 2 Not yet recruiting Peking University First Hospital Jul 21, 2026 Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients APG-2575 Phase 2 / Phase 3 Not yet recruiting The Affiliated People's Hospital of Ningbo University May 20, 2026 Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma APG-2575 Phase 2 Not yet recruiting Henan Cancer Hospital Mar 10, 2026 Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease APG-2575 Phase 2 Recruiting Ruijin Hospital Dec 9, 2025 Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma APG-2575 Phase 1 / Phase 2 Not yet recruiting First Affiliated Hospital of Zhejiang University Sep 8, 2025 Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). APG-2575 Phase 3 Recruiting Ascentage Pharma Group Inc. Oct 15, 2024 Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma Navitoclax Phase 2 Active, not recruiting Peter MacCallum Cancer Centre, Australia May 18, 2023 Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Navitoclax Phase 1 Active, not recruiting Jacqueline Garcia, MD Jul 13, 2022 Combination of Olaparib and Navitoclax in Women with HGSC and TNBC Navitoclax Phase 1 Active, not recruiting Sunnybrook Health Sciences Centre May 3, 2022 Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax Navitoclax Phase 1 Active, not recruiting City of Hope Medical Center Feb 3, 2022 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Navitoclax Phase 1 / Phase 2 Active, not recruiting St. Jude Children's Research Hospital Jan 14, 2022 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Navitoclax Phase 3 Active, not recruiting AbbVie Jul 13, 2020 Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Navitoclax Phase 1 Active, not recruiting AbbVie Jul 1, 2020 A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Navitoclax Phase 1 Active, not recruiting AbbVie Aug 1, 2019
Show all 24Diseases most associated with it Open Targets association score, 0 to 1; all associations
Neoplasm 0.60
Neurodegenerative disease 0.54
Prostate carcinoma 0.53
Plasma cell myeloma 0.50
Type 2 diabetes mellitus 0.49
Lymphoid neoplasm 0.45
Neoplasm of mature B-cells 0.45 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4860 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt P10415 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets